Signaling by the phosphoinositide 3-kinase family in immune cells

Annual Review of Immunology

Volumn 31, Issue , 2013, Pages 675-704

  Okkenhaug, Klaus ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Akt; Autophagy; Foxo; MTOR; PI3K; Signaling

Indexed keywords

GUANOSINE TRIPHOSPHATASE; MYOTUBULARIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN INPP4; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN P110BETA; PROTEIN P110DELTA; PROTEIN SHIP; PROTEIN TYROSINE KINASE; TEC KINASE; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CATALYSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL VACUOLE; CRYSTAL STRUCTURE; GERMINAL CENTER; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NONHUMAN; PHAGOCYTOSIS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CATALYTIC DOMAIN; ENDOCYTOSIS; HUMANS; MULTIGENE FAMILY; MULTIPROTEIN COMPLEXES; PHAGOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84875528574     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032712-095946     Document Type: Article

References (239)

1. Hawkins PT, Anderson KE, Davidson K, Stephens LR. 2006. Signalling through class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34:647-62
2. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7:606-19
3. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. 2010. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11:329-41
4. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. 1997. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22:267-72
5. Backer JM. 2008. The regulation and function of class III PI3Ks: novel roles for Vps34. Biochem. J. 410:1-17
6. Axe EL, Walker SA, ManifavaM, Chandra P, Roderick HL, et al. 2008. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. J. Cell Biol. 182:685-701
7. Ellson CD, AndersonKE, Morgan G, Chilvers ER, Lipp P, et al. 2001. Phosphatidylinositol 3-phosphate is generated in phagosomal membranes. Curr. Biol. 11:1631-35
8. Vieira O, Botelho R, Rameh L, Brachmann S, Matsuo T, et al. 2001. Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J. Cell Biol. 155:19-25
9. Simonsen A, Lippe R, Christoforidis S, Gaullier JM, Brech A, et al. 1998. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature 394:494-98
10. Schu PV, Takegawa K, Fry MJ, Stack JH, Waterfield MD, et al. 1993. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science 260:88-91
11. Simonsen A, Wurmser AE, Emr SD, Stenmark H. 2001. The role of phosphoinositides in membrane transport. Curr. Opin. Cell Biol. 13:485-92
12. Kihara A, Noda T, Ishihara N, Ohsumi Y. 2001. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J. Cell Biol. 152:519-30
13. Stack JH, Herman PK, Schu PV, Emr SD. 1993. A membrane-associated complex containing the Vps15 protein kinase and the Vps34 PI 3-kinase is essential for protein sorting to the yeast lysosome-like vacuole. EMBO J. 12:2195-204
14. Obara K, Ohsumi Y. 2011. PtdIns 3-kinase orchestrates autophagosome formation in yeast. J. Lipids 2011:498768
15. Nobukuni T, JoaquinM, Roccio M, Dann SG, Kim SY, et al. 2005. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. USA 102:14238-43
16. Jaber N, Dou Z, Chen JS, Catanzaro J, Jiang YP, et al. 2012. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc. Natl. Acad. Sci. USA 109:2003-8
17. Miller S, Tavshanjian B, Oleksy A, Perisic O, Houseman BT, et al. 2010. Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science 327:1638-42
18. Zhou X, Takatoh J, Wang F. 2011. The mammalian class 3 PI3K (PIK3C3) is required for early embryogenesis and cell proliferation. PLoS ONE 6:e16358
19. Willinger T, Flavell RA. 2012. Canonical autophagy dependent on the class III phosphoinositide-3 kinase Vps34 is required for naive T-cell homeostasis. Proc. Natl. Acad. Sci. USA 109:8670-75
20. McLeod IX, Zhou X, LiQJ, Wang F, He YW. 2011. The class III kinase Vps34 promotes T lymphocyte survival through regulating IL-7Rαsurface expression. J. Immunol. 187:5051-61
21. Anderson KE, Chessa TA, Davidson K, Henderson RB, Walker S, et al. 2010. PtdIns3P and Rac direct the assembly of the NADPH oxidase on a novel, pre-phagosomal compartment during FcR-mediated phagocytosis in primary mouse neutrophils. Blood 116:4978-89
22. Kanai F, Liu H, Field SJ, Akbary H, Matsuo T, et al. 2001. The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat. Cell Biol. 3:675-78
23. Ellson CD, Gobert-Gosse S, Anderson KE, Davidson K, Erdjument-Bromage H, et al. 2001. PtdIns(3)P regulates the neutrophil oxidase complex by binding to the PX domain of p40phox. Nat. Cell Biol. 3:679-82
24. Ellson C, Davidson K, Anderson K, Stephens LR, Hawkins PT. 2006. PtdIns3P binding to the PX domain of p40phox is a physiological signal in NADPH oxidase activation. EMBO J. 25:4468-78
25. Berger SB, Romero X, Ma C, Wang G, Faubion WA, et al. 2010. SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. Nat. Immunol. 11:920-27
26. Ma C, Wang N, Detre C, Wang G, O'Keeffe M, et al. 2012. Receptor signaling lymphocyte-activation molecule family 1 (Slamf1) regulates membrane fusion and NADPH oxidase 2 (NOX2) activity by recruiting a Beclin-1/Vps34/ ultraviolet radiation resistance-associated gene (UVRAG) complex. J. Biol. Chem. 287:18359-65
27. Ktistakis NT, Manifava M, Schoenfelder P, Rotondo S. 2012. How phosphoinositide 3-phosphate controls growth downstream of amino acids and autophagy downstream of amino acid withdrawal. Biochem. Soc. Trans. 40:37-43
28. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. 2012. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 8:445-544
29. Levine B, MizushimaN, VirginHW. 2011. Autophagy in immunity and inflammation. Nature 469:323-35
30. Yordy B, Iwasaki A. 2011. Autophagy in the control and pathogenesis of viral infection. Curr. Opin. Virol. 1:196-203
31. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. 2007. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315:1398-401
32. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593-96
33. Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, et al. 2010. In vivo requirement for Atg5 in antigen presentation by dendritic cells. Immunity 32:227-39
34. He MX, McLeod IX, JiaW, He YW.2012. Macroautophagy inTlymphocyte development and function. Front. Immunol. 3:22
35. PolsonHE, deLartigue J, Rigden DJ, ReedijkM, Urbe S, et al. 2010. Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation. Autophagy 6:506-22
36. Falasca M, Maffucci T. 2012. Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem. J. 443:587-601
37. Harris DP, Vogel P, Wims M, Moberg K, Humphries J, et al. 2011. Requirement for class II phosphoinositide 3-kinase C2αin maintenance of glomerular structure and function. Mol. Cell. Biol. 31:63-80
38. Harada K, Truong AB, Cai T, Khavari PA. 2005. The class II phosphoinositide 3-kinase C2β is not essential for epidermal differentiation. Mol. Cell. Biol. 25:11122-30
39. Anderson KE, Boyle KB, DavidsonK, Chessa TA, Kulkarni S, et al. 2008. CD18-dependent activation of the neutrophilNADPHoxidase during phagocytosis of Escherichia coli or Staphylococcus aureus is regulated by class III but not class I or II PI3Ks. Blood 112:5202-11
40. + channel KCa3.1 and CD4T-cells. Mol. Biol. Cell 20:3783-91
41. Srivastava S, Choudhury P, Li Z, Liu G, Nadkarni V, et al. 2006. Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1. Mol. Biol. Cell 17:146-54
42. Srivastava S, Ko K, Choudhury P, Li Z, Johnson AK, et al. 2006. Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells. Mol. Cell. Biol. 26:5595-602
43. + channel KCa3.1. Mol. Cell. Biol. 25:3630-38
44. Feske S, Skolnik EY, Prakriya M. 2012. Ion channels and transporters in lymphocyte function and immunity. Nat. Rev. Immunol. 12:532-47
45. Dove SK, Cooke FT, Douglas MR, Sayers LG, Parker PJ, et al. 1997. Osmotic stress activates phosphatidylinositol-3, 5-bisphosphate synthesis. Nature 390:187-92
46. Dove SK, DongK, KobayashiT, Williams FK, Michell RH. 2009. Phosphatidylinositol 3, 5-bisphosphate and Fab1p/PIKfyve underPPIn endo-lysosome function. Biochem. J. 419:1-13
47. +/-mice. J. Biol. Chem. 286:13404-13
48. Kerr MC, Wang JT, Castro NA, Hamilton NA, Town L, et al. 2010. Inhibition of the PtdIns(5) kinase PIKfyve disrupts intracellular replication of Salmonella. EMBO J. 29:1331-47
49. Hnia K, Vaccari I, Bolino A, Laporte J. 2012. Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology. Trends Mol. Med. 18:317-27
50. Robinson FL, Dixon JE. 2006. Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol. 16:403-12
51. Velichkova M, Juan J, Kadandale P, Jean S, Ribeiro I, et al. 2010. Drosophila Mtm and class II PI3K coregulate a PI(3)P pool with cortical and endolysosomal functions. J. Cell Biol. 190:407-25
52. Fruman DA. 2010. Regulatory subunits of class IA PI3K. Curr. Top. Microbiol. Immunol. 346:225-44
53. Castellano E, Downward J. 2011. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2:261-74
54. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, et al. 2002. Impaired B and T cell antigen receptor signaling in p110∞ PI 3-kinase mutant mice. Science 297:1031-34
55. Ramadani F, Bolland DJ, Garcon F, Emery JL, Vanhaesebroeck B, et al. 2010. The PI3K isoforms p110α and p110∞ are essential for pre-B cell receptor signaling and B cell development. Sci. Signal. 3:ra60
56. Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. 2010. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. USA 107:11381-86
57. Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, et al. 2011. PI3Kβplays a critical role in neutrophil activation by immune complexes. Sci. Signal. 4:ra23
58. Hirsch E, Katanaev VL, Garlanda C, AzzolinoO, PirolaL, et al. 2000. Central role forGprotein-coupled phosphoinositide 3-kinase γin inflammation. Science 287:1049-53
59. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, et al. 2000. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287:1040-46
60. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, et al. 2000. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287:1046-49
61. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, et al. 2002. Essential, nonredundant role for the phosphoinositide 3-kinase p110∞in signaling by the B-cell receptor complex. Mol. Cell. Biol. 22:8580-91
62. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, et al. 2002. A crucial role for the p110∞ subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196:753-63
63. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. 2003. Essential role of phosphoinositide 3-kinase ∞ in neutrophil directional movement. J. Immunol. 170:2647-54
64. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, et al. 2005. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11:936-43
65. Andrews S, Stephens LR, Hawkins PT. 2007. PI3K class IB pathway. Sci. STKE 2007:cm2
66. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, et al. 2008. The p110βisoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ. Proc. Natl. Acad. Sci. USA. 105:8292-97
67. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, et al. 2008. Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1:ra3
68. Jia S, Liu Z, Zhang S, Liu P, Zhang L, et al. 2008. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 454:776-79
69. Dbouk HA, Vadas O, Shymanets A, Burke JE, Salamon RS, et al. 2012. G protein-coupled receptormediated activation of p110βbyGβγis required for cellular transformation and invasiveness. Sci. Signal. 5:ra89
70. Saudemont A, Garcon F, Yadi H, Roche-Molina M, Kim N, et al. 2009. p110γ and p110∞ isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc. Natl. Acad. Sci. USA 106:5795-800
71. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, et al. 2004. Cutting edge: differential roles for phosphoinositide 3-kinases, p110γ and p110∞, in lymphocyte chemotaxis and homing. J. Immunol. 173:2236-40
72. Samuels Y, Waldman T. 2010. Oncogenic mutations of PIK3CA in human cancers. Curr. Top. Microbiol. Immunol. 347:21-41
73. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
74. Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. 2011. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 4:re2
75. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945-50. http://www.sanger.ac.uk/cosmic
76. Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B, et al. 2010. Structural effects of oncogenic PI3Kαmutations. Curr. Top. Microbiol. Immunol. 347:43-53
77. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, et al. 2007. The structure of a human p110α/p85αcomplex elucidates the effects of oncogenic PI3Kαmutations. Science 318:1744-48
78. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, et al. 2007. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317:239-42
79. Yu J, Wjasow C, Backer JM. 1998. Regulation of the p85/ p110αphosphatidylinositol 3-kinase. Distinct roles for the N-terminal and C-terminal SH2 domains. J. Biol. Chem. 273:30199-203
80. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, et al. 1998. Regulation of the p85/p110 phosphatidylinositol 3-kinase: stabilization and inhibition of the p110αcatalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18:1379-87
81. Burke JE, Vadas O, Berndt A, Finegan T, Perisic O, et al. 2011. Dynamics of the phosphoinositide 3-kinase p110∞interaction with p85αand membranes reveals aspects of regulation distinct from p110α. Structure 19:1127-37
82. Zhao L, Vogt PK. 2008. Helical domain and kinase domain mutations in p110αof phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 105:2652-57
83. SunM, Hillmann P, Hofmann BT, Hart JR, Vogt PK. 2010. Cancer-derived mutations in the regulatory subunit p85αof phosphoinositide 3-kinase function through the catalytic subunit p110α. Proc.Natl. Acad. Sci. USA. 107:15547-52
84. Wu H, Shekar SC, Flinn RJ, El-Sibai M, Jaiswal BS, et al. 2009. Regulation of class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110αand are disrupted in oncogenic p85 mutants. Proc. Natl. Acad. Sci. USA 106:20258-63
85. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, et al. 2007. Binding of Ras to phosphoinositide 3-kinase p110αis required for Ras-driven tumorigenesis in mice. Cell 129:957-68
86. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. 2006. Oncogenic transformation induced by the p110β, -γ, and -∞ isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 103:1289-94
87. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, et al. 1997. P110∞, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. USA 94:4330-35
88. Rodriguez-Viciana P, Sabatier C, McCormick F. 2004. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24:4943-54
89. Delgado P, Cubelos B, Calleja E, Martinez-Martin N, Cipres A, et al. 2009. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol. 10:880-88
90. Zhang X, Vadas O, Perisic O, Anderson KE, Clark J, et al. 2011. Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol. Cell 41:567-78
91. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, et al. 2006. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366-70
92. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. 2006. A pharmacological map of the PI3-K family defines a role for p110αin insulin signaling. Cell 125:733-47
93. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, et al. 2008. Angiogenesis selectively requires the p110αisoform of PI3K to control endothelial cell migration. Nature 453:662-66
94. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, et al. 2006. The p110αisoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl. Acad. Sci. USA 103:16296-300
95. Janas ML, Hodson D, Stamataki Z, Hill S, Welch K, et al. 2008. The effect of deleting p110∞ on the phenotype and function of PTEN-deficient B cells. J. Immunol. 180:739-46
96. Bilancio A, Okkenhaug K, CampsM, Emery JL, Ruckle T, et al. 2006. Key role of the p110∞isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110∞ function in B cells. Blood 107:642-50
97. Okkenhaug K, Ali K, Vanhaesebroeck B. 2007. Antigen receptor signalling: a distinctive role for the p110∞ isoform of PI3K. Trends Immunol. 28:80-87
98. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. 2007. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. USA 104:7809-14
99. Berndt A, Miller S, Williams O, Le DD, Houseman BT, et al. 2010. The p110∞ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol. 6:117-24
100. Tuveson DA, Carter RH, Soltoff SP, Fearon DT. 1993. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science 260:986-89
101. Leslie NR, Dixon MJ, Schenning M, Gray A, Batty IH. 2012. Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. Adv. Enzyme Regul. 52:205-13
102. Ward SG, Blunt MD. 2012. Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment and new opportunities. Front. Immunol. 3:226
103. Rameh LE, ArvidssonA, CarrawayKL3rd, Couvillon AD, Rathbun G, et al. 1997.Acomparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. J. Biol. Chem. 272:22059-66
104. Franke TF, Kaplan DR, Cantley LC, Toker A. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 275:665-68
105. LemmonMA, Ferguson KM. 2000. Signal-dependentmembrane targeting by pleckstrin homology (PH) domains. Biochem. J. 350(Pt. 1):1-18
106. Pauls SD, Lafarge ST, Landego I, Zhang T-t, Marshall AJ. 2012. The phosphoinositide 3-kinase signalling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front. Immunol. 3:224
107. Newton RH, Turka LA. 2012. Regulation of T cell homeostasis and responses by Pten. Front. Immunol. 3:151
108. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, et al. 2001. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14:523-34
109. Buckler JL, Walsh PT, Porrett PM, Choi Y, Turka LA. 2006. Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J. Immunol. 177:4262-66
110. Soond DR, Garcon F, Patton DT, Rolf J, Turner M, et al. 2012. Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. J. Immunol. 188:5935-43
111. Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, et al. 2006. Regulation of classswitch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25:245-57
112. Browne CD, Del Nagro CJ, Cato MH, Dengler HS, Rickert RC. 2009. Suppression of phosphatidylinositol 3, 4, 5-trisphosphate production is a key determinant of B cell anergy. Immunity 31:749-60
113. Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, et al. 2003. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 197:657-67
114. Kerr WG. 2011. Inhibitor and activator: dual functions for SHIP in immunity and cancer. Ann. N. Y. Acad. Sci. 1217:1-17
115. Miletic AV, Anzelon-Mills AN, Mills DM, Omori SA, Pedersen IM, et al. 2010. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J. Exp. Med. 207:2407-20
116. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, et al. 2010. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl. Acad. Sci. USA 107:22231-36
117. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, et al. 2009. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16:115-25
118. Lemmon MA. 2008. Membrane recognition by phospholipid-binding domains. Nat. Rev. Mol. Cell Biol. 9:99-111
119. + T cells. Immunity 23:263-74
120. Rapley J, Tybulewicz VL, Rittinger K. 2008. Crucial structural role for the PH and C1 domains of the Vav1 exchange factor. EMBO Rep. 9:655-61
121. Park WS, Heo WD, Whalen JH, O'Rourke NA, Bryan HM, et al. 2008. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol. Cell 30:381-92
122. Krugmann S, Anderson KE, Ridley SH, Risso N, McGregor A, et al. 2002. Identification of ARAP3, a novel PI3K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Mol. Cell 9:95-108.
123. Hedrick SM. 2009. The cunning little vixen: Foxo and the cycle of life and death. Nat. Immunol. 10:1057-63
124. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. 2012. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30:39-68
125. Finlay D, Cantrell DA. 2011. Metabolism, migration and memory in cytotoxicTcells. Nat. Rev. Immunol. 11:109-17
126. Fruman DA, Limon JJ. 2012. Akt and mTOR in B cell activation and differentiation. Front. Immunol. 3:228
127. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-74
128. Chin YR, Toker A. 2011. Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adhes. Migr. 5:211-14
129. Calamito M, Juntilla MM, Thomas M, Northrup DL, Rathmell J, et al. 2010. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 115:4043-50
130. Juntilla MM, Patil VD, Calamito M, Joshi RP, Birnbaum MJ, et al. 2010. AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood 115:4030-38
131. Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA. 2007. Akt1 and Akt2 are required for αβthymocyte survival and differentiation. Proc. Natl. Acad. Sci. USA 104:12105-10
132. Fayard E, Gill J, PaolinoM, Hynx D, Hollander GA, et al. 2007. Deletion of PKBα/Akt1 affects thymic development. PLoS ONE 2:e992
133. Mao C, Tili EG, Dose M, Haks MC, Bear SE, et al. 2007. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J. Immunol. 178:5443-53
134. Macintyre AN, Finlay D, PrestonG, Sinclair LV, Waugh CM, et al. 2011. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34:224-36
135. Amin RH, Schlissel MS. 2008. Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat. Immunol. 9:613-22
136. Dengler HS, Baracho GV, Omori SA, Bruckner S, Arden KC, et al. 2008. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9:1388-98
137. Fabre S, Carrette F, Chen J, Lang V, Semichon M, et al. 2008. FOXO1 regulates L-selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J. Immunol. 181:2980-89
138. Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, et al. 2008. KLF4 is a FOXO target gene that suppresses B cell proliferation. Int. Immunol. 20:671-81
139. Dejean AS, Beisner DR, Ch'en IL, Kerdiles YM, Babour A, et al. 2009. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat. Immunol. 10:504-13
140. Kerdiles YM, Beisner DR, Tinoco R, Dejean AS, Castrillon DH, et al. 2009. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10:176-84
141. Ouyang W, Beckett O, Flavell RA, Li MO. 2009. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity 30:358-71
142. Merkenschlager M, von Boehmer H. 2010. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J. Exp. Med. 207:1347-50
143. + regulatory T cells. Nat. Immunol. 11:618-27
144. Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, et al. 2010. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res. 70:4709-18
145. Alkhatib A, Werner M, Hug E, Herzog S, Eschbach C, et al. 2012. FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination. J. Exp. Med. 209:395-406
146. Graham JR, Hendershott MC, Terragni J, Cooper GM. 2010. mRNA degradation plays a significant role in the program of gene expression regulated by phosphatidylinositol 3-kinase signaling. Mol. Cell. Biol. 30:5295-305
147. Turner M, Hodson D. 2012. Regulation of lymphocyte development and function by RNA-binding proteins. Curr. Opin. Immunol. 24:160-65
148. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-93
149. Shaw RJ, Cantley LC. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-30
150. Salmond RJ, Emery J, Okkenhaug K, Zamoyska R. 2009. MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J. Immunol. 183:7388-97
151. + T cells. J. Exp. Med. 209:2441-53
152. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, et al. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290-303
153. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, et al. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496-501
154. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, et al. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332:1317-22
155. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, et al. 2011. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322-26
156. Shi LZ, Wang R, HuangG, Vogel P, Neale G, et al. 2011. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208:1367-76
157. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, et al. 2011. Control of TH17/Treg balance by hypoxiainducible factor 1. Cell 146:772-84
158. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159-68
159. + T cell differentiation. Immunity 36:374-87
160. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. 2005. Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol. 23:549-600
161. Li Z, Wahl MI, Eguinoa A, Stephens LR, Hawkins PT, et al. 1997. Phosphatidylinositol 3-kinase-γ activates Bruton's tyrosine kinase in concert with Src family kinases. Proc. Natl. Acad. Sci. USA 94:13820-25
162. Suzuki H, Matsuda S, Terauchi Y, Fujiwara M, Ohteki T, et al. 2003. PI3K and Btk differentially regulate B cell antigen receptor-mediated signal transduction. Nat. Immunol. 4:280-86
163. Matsuda S, Mikami Y, Ohtani M, Fujiwara M, Hirata Y, et al. 2009. Critical role of class IA PI3K for c-Rel expression in B lymphocytes. Blood 113:1037-44
164. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT. 2003. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett. 546:93-97
165. Welch HC, CoadwellWJ, Ellson CD, Ferguson GJ, Andrews SR, et al. 2002. P-Rex1, a PtdIns(3, 4, 5)P3-and Gβγ-regulated guanine-nucleotide exchange factor for Rac. Cell 108:809-21
166. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, et al. 2005. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106:1432-40
167. Lawson CD, Donald S, Anderson KE, Patton DT, Welch HC. 2011. P-Rex1 and Vav1 cooperate in the regulation of formyl-methionyl-leucyl-phenylalanine- dependent neutrophil responses. J. Immunol. 186:1467-76
168. Saveliev A, Vanes L, Ksionda O, Rapley J, Smerdon SJ, et al. 2009. Function of the nucleotide exchange activity of Vav1 in T cell development and activation. Sci. Signal. 2:ra83
169. Costa C, Barberis L, Ambrogio C, Manazza AD, Patrucco E, et al. 2007. Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase γ. Proc. Natl. Acad. Sci. USA 104:14354-59
170. Costa C, Germena G, Martin-Conte EL, Molineris I, Bosco E, et al. 2011. The RacGAP ArhGAP15 is a master negative regulator of neutrophil functions. Blood 118:1099-108
171. Craig HE, Coadwell J, Guillou H, Vermeren S. 2010. ARAP3 binding to phosphatidylinositol-(3, 4, 5)-trisphosphate depends on N-terminal tandemPHdomains and adjacent sequences. Cell Signal. 22:257-64
172. Gambardella L, Anderson KE, NussbaumC, Segonds-Pichon A, MargaridoT, et al. 2011. TheGTPaseactivating protein ARAP3 regulates chemotaxis and adhesion-dependent processes in neutrophils. Blood 118:1087-98
173. So L, Fruman DA. 2012. PI3K signalling in B-and T-lymphocytes: new developments and therapeutic advances. Biochem. J. 442:465-81
174. Okkenhaug K, Fruman DA. 2010. PI3Ks in lymphocyte signaling and development. Curr. Top. Microbiol. Immunol. 346:57-85
175. Fruman DA, Bismuth G. 2009. Fine tuning the immune response with PI3K. Immunol. Rev. 228:253-72
176. Okkenhaug K, VanhaesebroeckB. 2003. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3:317-30
177. Deane JA, Fruman DA. 2004. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22:563-98
178. Koyasu S. 2003. The role of PI3K in immune cells. Nat. Immunol. 4:313-19
179. Yilmaz OH, Valdez R, Theisen BK, GuoW, Ferguson DO, et al. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441:475-82
180. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441:518-22
181. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, et al. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325-39
182. Herzog S, Reth M, Jumaa H. 2009. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9:195-205
183. Corcoran AE, Smart FM, Cowling RJ, Crompton T, Owen MJ, et al. 1996. The interleukin-7 receptor αchain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. EMBO J. 15:1924-32
184. Osborne LC, DuthieKA, Seo JH, Gascoyne RD, Abraham N. 2010. Selective ablation of the YxxM motif of IL-7Rαsuppresses lymphomagenesis but maintains lymphocyte development. Oncogene 29:3854-64
185. Marshall AJ, Fleming HE, Wu GE, Paige CJ. 1998. Modulation of the IL-7 dose-response threshold during pro-B cell differentiation is dependent on pre-B cell receptor expression. J. Immunol. 161:6038-45
186. Herzog S, Hug E, Meixlsperger S, Paik JH, DePinho RA, et al. 2008. SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat. Immunol. 9:623-31
187. Werner M, Hobeika E, Jumaa H. 2010. Role of PI3K in the generation and survival of B cells. Immunol. Rev. 237:55-71
188. Llorian M, Stamataki Z, Hill S, Turner M, Martensson IL. 2007. The PI3K p110∞ is required for down-regulation of RAG expression in immature B cells. J. Immunol. 178:1981-85
189. Verkoczy L, Duong B, Skog P, Ait-AzzouzeneD, Puri K, et al. 2007. Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. J. Immunol. 178:6332-41
190. Tze LE, Schram BR, Lam KP, Hogquist KA, Hippen KL, et al. 2005. Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS Biol. 3:e82
191. Lam KP, Kuhn R, Rajewsky K. 1997. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90:1073-83
192. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/ βheterodimer. Cell 117:787-800
193. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, et al. 2009. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139:573-86
194. Garcon F, Patton DT, Emery JL, Hirsch E, Rottapel R, et al. 2008. CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood 111:1464-71
195. Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, et al. 2009. Phosphoinositide 3-kinase p110∞ regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183:5673-84
196. Rolf J, Bell SE, Kovesdi D, Janas ML, Soond DR, et al. 2010. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J. Immunol. 185:4042-52
197. Zhang TT, Makondo KJ, Marshall AJ. 2012. p110∞ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression. J. Immunol. 188:3700-8
198. Zhang TT, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, et al. 2008. Genetic or pharmaceutical blockade of p110∞ phosphoinositide 3-kinase enhances IgE production. J. Allergy Clin. Immunol. 122:811-19.e2
199. Khalil AM, Cambier JC, Shlomchik MJ. 2012. B cell receptor signal transduction in the GC is shortcircuited by high phosphatase activity. Science 336:1178-81
200. Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, et al. 2007. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 109:2894-902
201. Janas ML, Turner M. 2010. Stromal cell-derived factor 1α and CXCR4: newly defined requirements for efficient thymic β-selection. Trends Immunol. 31:370-76
202. Hagenbeek TJ, Naspetti M, Malergue F, Garcon F, Nunes JA, et al. 2004. The loss of PTEN allows TCR αβlineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J. Exp.Med. 200:883-94
203. JanasML, VaranoG, Gudmundsson K, Noda M, Nagasawa T, et al. 2010. Thymic development beyond β-selection requires phosphatidylinositol 3-kinase activation by CXCR4. J. Exp. Med. 207:247-61
204. Webb LM, Vigorito E, Wymann MP, Hirsch E, Turner M. 2005. Cutting edge: T cell development requires the combined activities of the p110γ and p110∞ catalytic isoforms of phosphatidylinositol 3-kinase. J. Immunol. 175:2783-87
205. Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, et al. 2007. Inactivation of PI3Kγ and PI3K∞ distorts T-cell development and causes multiple organ inflammation. Blood 110:2940-47
206. Swat W, Montgrain V, Doggett TA, Douangpanya J, Puri K, et al. 2006. Essential role of PI3K∞ and PI3Kγin thymocyte survival. Blood 107:2415-22
207. Kelly AP, Finlay DK, Hinton HJ, Clarke RG, Fiorini E, et al. 2007. Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J. 26:3441-50
208. Ciofani M, Zuniga-Pflucker JC. 2005. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nat. Immunol. 6:881-88
209. Wong GW, Knowles GC, Mak TW, Ferrando AA, Zuniga-Pflücker JC. 2012. HES1 opposes a PTENdependent check on survival, differentiation and proliferation of TCRβ-selected mouse thymocytes. Blood 120:1439-48
210. Perumalsamy LR, Marcel N, Kulkarni S, Radtke F, Sarin A. 2012. Distinct spatial andmolecular features of Notch pathway assembly in regulatory T cells. Sci. Signal. 5:ra53
211. JuntillaMM, Koretzky GA. 2008. Critical roles of the PI3K/Akt signaling pathway inTcell development. Immunol. Lett. 116:104-10
212. Hinton HJ, Alessi DR, Cantrell DA. 2004. The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell development. Nat. Immunol. 5:539-45
213. Finlay DK, Sinclair LV, Feijoo C, Waugh CM, Hagenbeek TJ, et al. 2009. Phosphoinositide-dependent kinase 1 controlsmigration andmalignant transformation but not cell growth and proliferation inPTENnull lymphocytes. J. Exp. Med. 206:2441-54
214. Acuto O, Michel F. 2003. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3:939-51
215. Holdorf AD, Green JM, Levin SD, Denny MF, Straus DB, et al. 1999. Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. J. Exp. Med. 190:375-84
216. Gigoux M, Shang J, Pak Y, Xu M, Choe J, et al. 2009. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 106:20371-76
217. Barber DF, Bartolome A, Hernandez C, Flores JM, Fernandez-Arias C, et al. 2006. Class IBphosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J. Immunol. 176:589-93
218. Martin AL, Schwartz MD, Jameson SC, Shimizu Y. 2008. Selective regulation of CD8 effector T cell migration by the p110γisoform of phosphatidylinositol 3-kinase. J. Immunol. 180:2081-88
219. Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y. 2008. The p110γ isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J. Leukoc. Biol. 84:814-23
220. Nombela-Arrieta C, Lacalle RA, Montoya MC, Kunisaki Y, Megias D, et al. 2004. Differential requirements for DOCK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing. Immunity 21:429-41
221. Okkenhaug K, Patton DT, Bilancio A, Garcon F, RowanWC, et al. 2006. The p110∞ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 177:5122-28
222. Soond DR, Bjorgo E, Moltu K, Dale VQ, Patton DT, et al. 2010. PI3K p110∞regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115:2203-13
223. Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, et al. 2011. PI3K∞drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J. Autoimmun. 36:278-87
224. Nashed BF, Zhang T, Al-Alwan M, Srinivasan G, Halayko AJ, et al. 2007. Role of the phosphoinositide 3-kinase p110∞ in generation of type 2 cytokine responses and allergic airway inflammation. Eur. J. Immunol. 37:416-24
225. Kurebayashi Y, Nagai S, Ikejiri A, OhtaniM, Ichiyama K, et al. 2012. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. Cell Rep. 1:360-73
226. Rommel C, Camps M, Ji H. 2007. PI3K∞ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7:191-201
227. Banham-Hall E, Clatworthy MR, Okkenhaug K. 2012. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol. J. 6:245-58
228. Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S, et al. 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3:875-81
229. + regulatory T cells. J. Immunol. 177:6598-602
230. Soond DR, Slack EC, Garden OA, Patton DT, Okkenhaug K. 2012. Does the PI3K pathway promote or antagonize regulatory T cell development and function? Front. Immunol. 3:244
231. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, et al. 2008. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 105:7797-802
232. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, et al. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460:108-12
233. + T cell memory and tumor immunity. Immunity 34:541-53
234. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 32:67-78
235. Liu D, Zhang T, Marshall AJ, Okkenhaug K, Vanhaesebroeck B, et al. 2009. The p110∞ isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J. Immunol. 183:1921-33
236. Gold MR, Puri KD. 2012. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front. Immunol. 3:256
237. Fruman DA, Rommel C. 2011. PI3K∞inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 1:562-72
238. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, et al. 2011. CAL-101, a p110∞selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117:591-94
239. Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, et al. 2012. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 21:459-72